Cite

    Magnus Johnsson et al.. “No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.” Multiple sclerosis, vol. 28, 2022, pp. 2070–2080. http://access.bl.uk/ark:/81055/vdc_100163377495.0x00002a